Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Tag: liraglutide


Effects of Liraglutide on Cardiovascular Outcomes in Patients with Type 2 Diabetes with or Without History of Myocardial Infarction or Stroke: A Post Hoc Analysis from the LEADER Trial

October 3rd 2018

In this post hoc analysis of patients with T2D and high cardiovascular risk, liraglutide reduced cardiovascular outcomes both in patients with a history of MI/stroke and in those with established atherosclerotic cardiovascular disease without MI/stroke. The cardiovascular effect appeared neutral in patients with cardiovascular risk factors alone (Circulation)

Categories: Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Type 2 Diabetes

The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure

May 30th 2018

This review indicates that GLP-1 has no short-term effect on REE but may decrease DIT. The GLP-1RA exenatide and liraglutide had a neutral effect on REE, although it was not possible to rule out an increase in REE following prolonged treatment (Diabetes Research and Clinical Practice)

Categories: Medication, News
Tags: exenatide, GLP1, liraglutide

Categories: Medication
Tags: exenatide, GLP1, liraglutide

Myocardial Infarction Subtypes in Patients with Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (From the LEADER Trial)

March 21st 2018

This analysis showed that liraglutide reduces the incidence of MIs in patients with type 2 DM at high CV risk, and may impact the clinical outcomes of MI (American Journal of Cardiology)

Categories: Cardiovascular, News
Tags: liraglutide, Type 2 Diabetes

Categories: Cardiovascular
Tags: liraglutide, Type 2 Diabetes

Insulin Tolerance Test Predicts Non Response vs. Sustained Efficacy of Liraglutide on Glycemic Control in Type 2 Diabetes Patients

December 16th 2017

This study suggests ITT as an efficient test to discriminate non–response from long-term efficacy before initiating Liraglutide. ITT could therefore help avoiding “try and see” prescription pattern by using a more precise and patient-centered strategy in order to reduce inertia in adapting treatment and so reduce subsequent complications (Diabetes Research and Clinical Practice)

Categories: News, Screening
Tags: ITT, liraglutide, Response, Type 2 Diabetes

Categories: Screening
Tags: ITT, liraglutide, Response, Type 2 Diabetes

Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease

December 5th 2017

With similar glycemic control, the Liraglutide (1.2 mg/d) monotherapy showed the better effects than either Metformin alone, or combination of Liraglutide and Metformin on lipid metabolism and cardiovascular function (Lipids in Health and Disease)

Categories: Medication, News
Tags: liraglutide, metformin, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, metformin, Type 2 Diabetes

Liraglutide and Renal Outcomes in Type 2 Diabetes

August 30th 2017

This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo (NEJM)

Categories: Medication, News
Tags: liraglutide, renal, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, renal, Type 2 Diabetes

Obese, overweight with risk factors: liraglutide (Saxenda)

June 27th 2017

This evidence summary discusses 4 randomised controlled trials (RCTs) in adults who were obese or overweight (BMI 27 kg/m2 or above) with a variety of weight-related comorbidities including dyslipidaemia, hypertension, type 2 diabetes and obstructive sleep apnoea (NICE)

Categories: News, Obesity
Tags: liraglutide, NICE

Categories: Obesity
Tags: liraglutide, NICE

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

May 16th 2017

In a population with type 2 diabetes at high cardiovascular risk, there were numerically fewer events of acute pancreatitis among liraglutide-treated patients (regardless of previous history of pancreatitis) compared with the placebo group (Diabetes Care)

Categories: Medication, News
Tags: liraglutide, pancreatitis, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, pancreatitis, Type 2 Diabetes

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes

February 23rd 2017

Liraglutide 3·0 mg might provide health benefits in terms of reduced risk of diabetes in individuals with obesity and prediabetes (The Lancet)

Categories: News, Treatment
Tags: liraglutide, risk reduction, Type 2 Diabetes

Categories: Treatment
Tags: liraglutide, risk reduction, Type 2 Diabetes

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

December 28th 2016

A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected (Diabetes Care)

Categories: Medication, News
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Pancreas, sitagliptin, Type 2 Diabetes

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial

November 3rd 2016

Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed  (European Journal of Heart Failure)

Categories: Medication, News
Tags: chronic heart failure, liraglutide, ventricular function

Categories: Medication
Tags: chronic heart failure, liraglutide, ventricular function

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

July 27th 2016

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo (NEJM)

Categories: Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Type 2 Diabetes

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

November 20th 2015

Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies (The Lancet)

Categories: Hepatology, News
Tags: liraglutide, NAFLD

Categories: Hepatology
Tags: liraglutide, NAFLD

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)

October 29th 2015

Adding liraglutide to multiple daily insulin injections in people with type 2 diabetes improves glycaemic control without an increased risk of hypoglycaemia, reduces body weight, and enables patients to lower their insulin doses (BMJ)

Categories: Medication, News
Tags: liraglutide, Type 2 Diabetes

Categories: Medication
Tags: liraglutide, Type 2 Diabetes

Victoza® (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

September 16th 2015

Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 diabetes (Novo Nordisk)

Categories: Medication, News
Tags: liraglutide, Victoza

Categories: Medication
Tags: liraglutide, Victoza

Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes

August 24th 2015

Based on a risk/benefit assessment of the overall dataset from the two ADJUNCT trials, Novo Nordisk does currently not intend to submit an application to expand the label of Victoza® for use in type 1 diabetes (Novo Nordisk)

Categories: Medication, News
Tags: liraglutide

Categories: Medication
Tags: liraglutide

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial

August 18th 2015

Among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide (3.0 mg) daily, compared with placebo, resulted in weight loss over 56 weeks. Further studies are needed to evaluate longer-term efficacy and safety (JAMA)

Categories: News, Obesity
Tags: liraglutide, Type 2 Diabetes

Categories: Obesity
Tags: liraglutide, Type 2 Diabetes

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

July 2nd 2015

In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control (NEJM)

Categories: Medication, News
Tags: liraglutide

Categories: Medication
Tags: liraglutide

United States first country to launch Saxenda

April 23rd 2015

Novo Nordisk announce that Saxenda® (liraglutide 3 mg) is now available in the United States (US). Saxenda® is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada

Categories: Medication, News
Tags: liraglutide, Saxenda

Categories: Medication
Tags: liraglutide, Saxenda

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

April 23rd 2015

Lixisenatide and liraglutide improved glycemic control in optimized insulin glargine-treated T2D albeit with contrasting mechanisms of action and differing safety profiles (Diabetes Care)

Categories: Medication, News
Tags: liraglutide, lixisenatide

Categories: Medication
Tags: liraglutide, lixisenatide
  • 1
  • 2
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

MSDNapp DiabetesNovo NordiskAstraZeneca

Silver Sponsors

Abbott Diabetes CareSanofi DiabetesWelsh Endocrinology and Diabetes Society (WEDS)Amgen

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin cancer CGM closed-loop dapagliflozin DPP4 Empagliflozin Europe exenatide exercise GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE OGTT pioglitazone pregnancy retinopathy RYGB SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2019 Glycosmedia Partnership